Position Statement

on

Electronic Surface Brachytherapy

for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinomas (SCC)

(Approved by the Board of Directors November 13, 2013; revised March 22, 2014; revised August 9, 2014)

Delivery of surface x-rays using electronic surface brachytherapy differ from other surface-conforming brachytherapy technologies and from traditional external beam radiation in that the radiation is generated without the use of a radioisotope or linear accelerator.

Several modalities exist to treat basal and squamous cell carcinoma. Dermatologists should discuss treatment options with patients and determine the most appropriate treatment for patients based on cure rates, long term clinical and aesthetic outcome, patient's age and medical circumstances, patient's desires, coverage criteria, and full disclosure of all the risks and benefits of each treatment modality.

This Position Statement is intended to offer dermatologists guiding principles regarding provision of electronic surface brachytherapy services in order to provide high quality care for patients, but is not intended to establish a legal or medical standard of care.

1. Based on current evidence, surgical management remains the most effective treatment for BCC and SCC, providing the highest cure rates. 1-5

2. The Academy supports consideration of electronic surface brachytherapy as a secondary option for the treatment of BCC and SCC, for use in special circumstances, such as when surgical intervention is contraindicated6,7 or refused and after the benefits and risks of treatment alternatives have been discussed with the patient.

3. The Academy believes additional research is needed on electronic surface brachytherapy particularly on long term outcomes. 1-3

4. Electronic surface brachytherapy should not be administered by a dermatologist, per current manufacturer’s recommendations.

5. Dermatologists and their staff need to be aware of, and comply with, the full scope of federal and state laws and regulations governing the provision and billing of electronic surface brachytherapy services. Many states have regulations that establish specific educational and training requirements for those administering electronic surface brachytherapy, and these regulations can vary considerably from state to state. In addition, the regulatory environment is dynamic, with some states now engaged in rulemaking for these systems.

---

1 The Academy has issued a position statement on superficial radiation therapy. See http://www.aad.org/Forms/Policies/ps.aspx
2 To access state radiation safety agency contact information and/or regulations see link to The Conference of Radiation Control Program Directors website: http://www.crcpd.org/Map/default.aspx.
6. Electronic surface brachytherapy devices are being marketed to dermatologists as technologically advanced devices with significant current and future revenue streams. The Academy’s Code of Ethics for Dermatologists precludes patient management based on business models designed solely for the financial gain to the dermatology practice, without adequate concern for the best interests of the patient. Such an approach would undermine quality of care and compromise patient safety, and could subject the practice to ethical scrutiny.

7. It is important that any practice using electronic brachytherapy or similar therapies expend appropriate efforts to understand and use proper CPT coding for the service that is verified by an authoritative entity other than the device manufacturer, such as the local Medicare carrier or relevant private payer.

8. Further, the utilization of CPT codes related to electronic surface brachytherapy has been rapidly increasing. The Academy is concerned that a continued rapid increase in utilization of this service may draw scrutiny from private payers, federal agencies, including the Centers for Medicare and Medicaid Services (CMS) Members of Congress, and federal watchdogs. The results of such scrutiny could lead to relevant CPT code revisions, re-evaluations of reimbursement levels with likely decreases in payment for electronic surface brachytherapy, and restrictions on access to therapy via private insurance-generated qualifying criteria and Medicare Contractor-instituted Local Coverage Determinations.

9. Dermatologists should also be mindful when they consider adopting business models that implicate the Stark physician self-referral law or federal anti-Kickback statute which rely on the provider’s ability to refer patients to entities in which the provider or the provider’s family members have a financial interest. Congress and federal agencies have been highly critical of self-referral’s role in Medicare Part B expenditures’ rapid growth.7

References